secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001193125-26-122784
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports $49.1M EKTERLY revenue in 8mo transition period, 1,702 patient start forms
--------------------------------------------------------------------------------

- Global net product revenue of $49.1M from EKTERLY (sebetralstat) for May–Dec 2025; first commercial sales since launch on July 7, 2025.
- 1,702 patient start forms received in US through Feb 2026, nearly 20% of HAE population; 724 unique prescribers activated.
- R&D expenses $33.4M (down from $52.2M YoY); SG&A $124.7M (up from $64.9M) due to commercialization costs.
- Cash, equivalents and marketable securities $300.2M as of Dec 31, 2025; company expects to fund through profitability.
- Pediatric Phase 3 KONFIDENT-KID trial fully enrolled; interim data to be presented at 2026 Global Angioedema Summit; NDA filing planned Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312526122784/0001193125-26-122784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312526122784/d127514d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-122784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer